Lawmakers question Emergent BioSolutions over J&J vaccine

More issues surround Johnson & Johnson as it struggles to get its COVID-19 vaccine back on track in the United States. Questions remain about the vaccine's connection to rare blood clots and questions remain about Emergent BioSolutions, the company making the shot in Baltimore. On Monday, Emergent BioSolutions confirmed it stopped making the J&J vaccine, also known as the Janssen vaccine, at its Baltimore plant at the request of the Food and Drug Administration on Friday.